The present invention includes a composition and method for treating a glioblastoma in a human or animal subject comprising the steps of: identifying the human or animal subject in need of treatment of a glioblastoma, wherein the human or animal is no longer responsive to at least one of ...
Transforming GBM into a treatable entity will require new paradigms in cancer biology and the understanding of the mechanisms underlying GBM invasion, treatment resistance and recurrence. Like most solid tumors, GBMs consist of heterogeneous cancer cells (Faria et al., 2006), as well as competent ...
As mentioned above, treating GBM is challenging, and most patients die because of the disease, highlighting the importance of researching new therapeutic approaches. The standard treatment, known as the Stupp protocol, applied to GBM-diagnosed patients, implies surgery, if possible, to eliminate the...
In Table1, we summarized the FINs that have been reported for GBM treatment. These FINs findings also indicate that targeted ferroptosis is a promising GBM treatment strategy. Furthermore, an innovative GBM chemotherapy that locally targets ferroptosis was reported last year. Zhang et al. designed ...
Glioblastoma remains to be a highly destructive type of tumor despite availability of treatment strategies like surgery, chemotherapy, and radiation. Advances in the field of cancer biology have revolutionized therapy by allowing targeting of tumor-specific molecular deregulation. In this review, we ...
Cold atmospheric plasma (CAP), a near room temperature ionized gas, has shown potential application in many branches of medicine, particularly in cancer treatment. In previous studies, the biological effect of CAP on cancer cells and other mammalian cell
developing immunotherapy approaches that specifically target tumor cell subpopulations might be a new direction for GBM treatment. Second, the highly invasive capacity of GBM cells might contribute to tumor recurrence and treatment resistance [205]. The different invasive potentials of GBM cells increase ...
acta neuropathol commun (2020) 8:209 Page 5 of 9 that tumor growth could be attenuated by targeted drug treatment in some of the mutation/amplification com- binations. Finally, they showcased the suitability of their system for use in large-scale drug screening by modifying the tumor cells ...
Article Open access 25 June 2020 Introduction Glioblastoma (GBM) is the most common primary malignant brain tumor and one of the deadliest types of cancer1. GBM comprises 50% of all malignant brain tumors with over 14,000 new cases expected in 2023 in the US1. Current treatment includes surg...
Patients with IDH-wild-type glioblastomas have a poor five-year survival rate along with limited treatment efficacy due to immune cell (glioma-associated microglia and macrophages) infiltration promoting tumour growth and resistance. To enhance therapeutic options, our study investigated the unique RNA–...